T. Noesselt

Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.

M. Rezai, P. Fasching, L. Häberle, 2018, European journal of cancer.

Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients

M. Rezai, P. Fasching, L. Häberle, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

First Prospective Cross-Sectional Study on the Impact of Immigration Background and Education in Early Detection of Breast Cancer

T. Dörk, P. Hillemanns, T. Park-Simon, 2020, Breast Care.

Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study

M. Rezai, M. Beckmann, P. Fasching, 2019, BMC Cancer.

Three Cases of Arcanobacterium haemolyticum Associated with Abscess Formation and Cellulitis

J. Maerker, S. Dobinsky, A. Rücker, 1999, European Journal of Clinical Microbiology and Infectious Diseases.

Multifocal invasive ductal breast cancer with osteoclast-like giant cells: a case report

G. Richter, C. Uleer, T. Noesselt, 2011, Journal of medical case reports.

Results of modified burch colposuspension in patients with genuine stress incontinence and hypotonic urethra or recurrent stress incontinence

T. Noesselt, H. Wolf, 1993, International Urogynecology Journal.

Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study

M. Rezai, M. Beckmann, P. Fasching, 2019, BMC Cancer.

Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.

M. Rezai, M. Beckmann, P. Fasching, 2016, Breast care.

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

M. Rezai, T. Fehm, T. Kühn, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.